Skip to main content
Top
Published in: Abdominal Radiology 1/2018

01-01-2018

Hepatocellular carcinoma imaging systems: why they exist, how they have evolved, and how they differ

Authors: An Tang, Irene Cruite, Donald G. Mitchell, Claude B. Sirlin

Published in: Abdominal Radiology | Issue 1/2018

Login to get access

Abstract

Over the past 16 years, several scientific organizations have proposed systems that incorporate imaging for surveillance, diagnosis, staging, treatment, and monitoring of treatment response of hepatocellular carcinoma (HCC). These systems are needed to standardize the acquisition, interpretation, and reporting of liver imaging examinations; help differentiate benign from malignant observations; improve consistency between radiologists; and provide guidance for management of HCC. This review article discusses the historical evolution of HCC imaging systems. We indicate the features differentiating these systems, including target population, screening and surveillance algorithm, diagnostic imaging modalities, diagnostic scope, expertise and technical requirements, terminology, major and ancillary imaging features, staging and transplant eligibility, and assessment of treatment response. We highlight the potential benefits of unifying the systems, which we anticipate will enable sharing, pooling, and meta-analysis of data; facilitate multi-center trials; and accelerate dissemination of knowledge.
Literature
1.
go back to reference Ferenci P, Fried M, Labrecque D, et al. (2010) Hepatocellular carcinoma (HCC): a global perspective. J Clin Gastroenterol 44:239–245CrossRefPubMed Ferenci P, Fried M, Labrecque D, et al. (2010) Hepatocellular carcinoma (HCC): a global perspective. J Clin Gastroenterol 44:239–245CrossRefPubMed
2.
go back to reference Altekruse SF, McGlynn KA, Reichman ME (2009) Hepatocellular carcinoma incidence, mortality, and survival trends in the United States from 1975 to 2005. J Clin Oncol 27:1485–1491CrossRefPubMedPubMedCentral Altekruse SF, McGlynn KA, Reichman ME (2009) Hepatocellular carcinoma incidence, mortality, and survival trends in the United States from 1975 to 2005. J Clin Oncol 27:1485–1491CrossRefPubMedPubMedCentral
3.
go back to reference Lingvay I, Raskin P, Szczepaniak LS (2007) Effect of insulin-metformin combination on hepatic steatosis in patients with type 2 diabetes. J Diabetes Complicat 21:137–142CrossRefPubMedPubMedCentral Lingvay I, Raskin P, Szczepaniak LS (2007) Effect of insulin-metformin combination on hepatic steatosis in patients with type 2 diabetes. J Diabetes Complicat 21:137–142CrossRefPubMedPubMedCentral
4.
go back to reference Llovet JM, Di Bisceglie AM, Bruix J, et al. (2008) Design and endpoints of clinical trials in hepatocellular carcinoma. J Natl Cancer Inst 100:698–711CrossRefPubMed Llovet JM, Di Bisceglie AM, Bruix J, et al. (2008) Design and endpoints of clinical trials in hepatocellular carcinoma. J Natl Cancer Inst 100:698–711CrossRefPubMed
5.
go back to reference Bruix J, Sherman M, Llovet JM, et al. (2001) Clinical management of hepatocellular carcinoma. Conclusions of the Barcelona-2000 EASL conference. European Association for the Study of the Liver. J Hepatol 35:421–430CrossRefPubMed Bruix J, Sherman M, Llovet JM, et al. (2001) Clinical management of hepatocellular carcinoma. Conclusions of the Barcelona-2000 EASL conference. European Association for the Study of the Liver. J Hepatol 35:421–430CrossRefPubMed
6.
go back to reference Cruite I, Tang A, Sirlin CB (2013) Imaging-based diagnostic systems for hepatocellular carcinoma. AJR Am J Roentgenol 201:41–55CrossRefPubMed Cruite I, Tang A, Sirlin CB (2013) Imaging-based diagnostic systems for hepatocellular carcinoma. AJR Am J Roentgenol 201:41–55CrossRefPubMed
7.
go back to reference Tang A, Cruite I, Sirlin CB (2013) Toward a standardized system for hepatocellular carcinoma diagnosis using computed tomography and MRI. Expert Rev Gastroenterol Hepatol 7:269–279CrossRefPubMed Tang A, Cruite I, Sirlin CB (2013) Toward a standardized system for hepatocellular carcinoma diagnosis using computed tomography and MRI. Expert Rev Gastroenterol Hepatol 7:269–279CrossRefPubMed
9.
10.
go back to reference Poon D, Anderson BO, Chen LT, et al. (2009) Management of hepatocellular carcinoma in Asia: consensus statement from the Asian Oncology Summit 2009. Lancet Oncol 10:1111–1118CrossRefPubMed Poon D, Anderson BO, Chen LT, et al. (2009) Management of hepatocellular carcinoma in Asia: consensus statement from the Asian Oncology Summit 2009. Lancet Oncol 10:1111–1118CrossRefPubMed
11.
go back to reference Omata M, Lesmana LA, Tateishi R, et al. (2010) Asian Pacific Association for the Study of the Liver consensus recommendations on hepatocellular carcinoma. Hepatol Int 4:439–474CrossRefPubMedPubMedCentral Omata M, Lesmana LA, Tateishi R, et al. (2010) Asian Pacific Association for the Study of the Liver consensus recommendations on hepatocellular carcinoma. Hepatol Int 4:439–474CrossRefPubMedPubMedCentral
12.
go back to reference Van Vlierberghe H, Borbath I, Delwaide J, et al. (2004) BASL guidelines for the surveillance, diagnosis and treatment of hepatocellular carcinoma. Acta Gastroenterol Belg 67:14–25PubMed Van Vlierberghe H, Borbath I, Delwaide J, et al. (2004) BASL guidelines for the surveillance, diagnosis and treatment of hepatocellular carcinoma. Acta Gastroenterol Belg 67:14–25PubMed
13.
go back to reference European Association for the Study of the Liver, European Organisation for Research and Treatment of Cancer (2012) EASL-EORTC clinical practice guidelines: management of hepatocellular carcinoma. J Hepatol 56:908–943CrossRef European Association for the Study of the Liver, European Organisation for Research and Treatment of Cancer (2012) EASL-EORTC clinical practice guidelines: management of hepatocellular carcinoma. J Hepatol 56:908–943CrossRef
14.
go back to reference Jelic S (2009) Hepatocellular carcinoma: ESMO clinical recommendations for diagnosis, treatment and follow-up. Ann Oncol 20(Suppl 4):41–45PubMed Jelic S (2009) Hepatocellular carcinoma: ESMO clinical recommendations for diagnosis, treatment and follow-up. Ann Oncol 20(Suppl 4):41–45PubMed
15.
go back to reference Parikh P, Malhotra H, Jelic S (2008) Hepatocellular carcinoma: ESMO clinical recommendations for diagnosis, treatment and follow-up. Ann Oncol 19(Suppl 2):ii27–ii28PubMed Parikh P, Malhotra H, Jelic S (2008) Hepatocellular carcinoma: ESMO clinical recommendations for diagnosis, treatment and follow-up. Ann Oncol 19(Suppl 2):ii27–ii28PubMed
16.
go back to reference Makuuchi M, Kokudo N (2006) Clinical practice guidelines for hepatocellular carcinoma: the first evidence based guidelines from Japan. World J Gastroenterol 12:828–829CrossRefPubMedPubMedCentral Makuuchi M, Kokudo N (2006) Clinical practice guidelines for hepatocellular carcinoma: the first evidence based guidelines from Japan. World J Gastroenterol 12:828–829CrossRefPubMedPubMedCentral
17.
go back to reference Makuuchi M, Kokudo N, Arii S, et al. (2008) Development of evidence-based clinical guidelines for the diagnosis and treatment of hepatocellular carcinoma in Japan. Hepatol Res 38:37–51CrossRefPubMed Makuuchi M, Kokudo N, Arii S, et al. (2008) Development of evidence-based clinical guidelines for the diagnosis and treatment of hepatocellular carcinoma in Japan. Hepatol Res 38:37–51CrossRefPubMed
18.
go back to reference Kudo M, Matsui O, Izumi N, et al. (2014) JSH consensus-based clinical practice guidelines for the management of hepatocellular carcinoma: 2014 update by the Liver Cancer Study Group of Japan. Liver Cancer 3:458–468CrossRefPubMedPubMedCentral Kudo M, Matsui O, Izumi N, et al. (2014) JSH consensus-based clinical practice guidelines for the management of hepatocellular carcinoma: 2014 update by the Liver Cancer Study Group of Japan. Liver Cancer 3:458–468CrossRefPubMedPubMedCentral
19.
go back to reference Korean Liver Cancer Study Group, National Cancer Center (2015) 2014 Korean Liver Cancer Study Group-National Cancer Center Korea practice guideline for the management of hepatocellular carcinoma. Korean J Radiol 16:465–522CrossRef Korean Liver Cancer Study Group, National Cancer Center (2015) 2014 Korean Liver Cancer Study Group-National Cancer Center Korea practice guideline for the management of hepatocellular carcinoma. Korean J Radiol 16:465–522CrossRef
21.
go back to reference Benson AB 3rd, D’Angelica MI, Abrams TA, et al. (2016) NCCN clinical practice guidelines in oncology: hepatobiliary cancers. J Natl Compr Cancer Netw 2:2016 Benson AB 3rd, D’Angelica MI, Abrams TA, et al. (2016) NCCN clinical practice guidelines in oncology: hepatobiliary cancers. J Natl Compr Cancer Netw 2:2016
22.
go back to reference Abdo AA, Al Abdul Karim H, Al Fuhaid T, et al. (2007) Saudi gastroenterology association guidelines for the diagnosis and management of hepatocellular carcinoma: summary of recommendations. Saudi J Gastroenterol 13:45–48CrossRefPubMed Abdo AA, Al Abdul Karim H, Al Fuhaid T, et al. (2007) Saudi gastroenterology association guidelines for the diagnosis and management of hepatocellular carcinoma: summary of recommendations. Saudi J Gastroenterol 13:45–48CrossRefPubMed
24.
go back to reference Ferenci P, Fried M, Labrecque D, et al. (2010) World Gastroenterology Organisation Guideline. Hepatocellular carcinoma (HCC): a global perspective. J Gastrointest Liver Dis 19:311–317 Ferenci P, Fried M, Labrecque D, et al. (2010) World Gastroenterology Organisation Guideline. Hepatocellular carcinoma (HCC): a global perspective. J Gastrointest Liver Dis 19:311–317
25.
go back to reference Pinter M, Hucke F, Graziadei I, et al. (2012) Advanced-stage hepatocellular carcinoma: transarterial chemoembolization versus sorafenib. Radiology 263:590–599CrossRefPubMed Pinter M, Hucke F, Graziadei I, et al. (2012) Advanced-stage hepatocellular carcinoma: transarterial chemoembolization versus sorafenib. Radiology 263:590–599CrossRefPubMed
26.
go back to reference Lopez PM, Villanueva A, Llovet JM (2006) Systematic review: evidence-based management of hepatocellular carcinoma—an updated analysis of randomized controlled trials. Aliment Pharmacol Ther 23:1535–1547CrossRefPubMed Lopez PM, Villanueva A, Llovet JM (2006) Systematic review: evidence-based management of hepatocellular carcinoma—an updated analysis of randomized controlled trials. Aliment Pharmacol Ther 23:1535–1547CrossRefPubMed
27.
go back to reference Sutherland LM, Williams JA, Padbury RT, et al. (2006) Radiofrequency ablation of liver tumors: a systematic review. Arch Surg 141:181–190CrossRefPubMed Sutherland LM, Williams JA, Padbury RT, et al. (2006) Radiofrequency ablation of liver tumors: a systematic review. Arch Surg 141:181–190CrossRefPubMed
28.
go back to reference Marrero JA, Feng Z, Wang Y, et al. (2009) Alpha-fetoprotein, des-gamma carboxyprothrombin, and lectin-bound alpha-fetoprotein in early hepatocellular carcinoma. Gastroenterology 137:110–118CrossRefPubMedPubMedCentral Marrero JA, Feng Z, Wang Y, et al. (2009) Alpha-fetoprotein, des-gamma carboxyprothrombin, and lectin-bound alpha-fetoprotein in early hepatocellular carcinoma. Gastroenterology 137:110–118CrossRefPubMedPubMedCentral
29.
go back to reference Chou R, Cuevas C, Fu R, et al. (2015) Imaging techniques for the diagnosis of hepatocellular carcinoma: a systematic review and meta-analysis. Ann Intern Med 162:697–711CrossRefPubMed Chou R, Cuevas C, Fu R, et al. (2015) Imaging techniques for the diagnosis of hepatocellular carcinoma: a systematic review and meta-analysis. Ann Intern Med 162:697–711CrossRefPubMed
30.
go back to reference Bret PM, Labadie M, Bretagnolle M, et al. (1988) Hepatocellular carcinoma: diagnosis by percutaneous fine needle biopsy. Gastrointest Radiol 13:253–255CrossRefPubMed Bret PM, Labadie M, Bretagnolle M, et al. (1988) Hepatocellular carcinoma: diagnosis by percutaneous fine needle biopsy. Gastrointest Radiol 13:253–255CrossRefPubMed
31.
go back to reference Giorgio A, Tarantino L, de Stefano G, et al. (2003) Complications after interventional sonography of focal liver lesions: a 22-year single-center experience. J Ultrasound Med 22:193–205CrossRefPubMed Giorgio A, Tarantino L, de Stefano G, et al. (2003) Complications after interventional sonography of focal liver lesions: a 22-year single-center experience. J Ultrasound Med 22:193–205CrossRefPubMed
32.
go back to reference Caturelli E, Solmi L, Anti M, et al. (2004) Ultrasound guided fine needle biopsy of early hepatocellular carcinoma complicating liver cirrhosis: a multicentre study. Gut 53:1356–1362CrossRefPubMedPubMedCentral Caturelli E, Solmi L, Anti M, et al. (2004) Ultrasound guided fine needle biopsy of early hepatocellular carcinoma complicating liver cirrhosis: a multicentre study. Gut 53:1356–1362CrossRefPubMedPubMedCentral
33.
go back to reference Scholmerich J, Schacherer D (2004) Diagnostic biopsy for hepatocellular carcinoma in cirrhosis: useful, necessary, dangerous, or academic sport? Gut 53:1224–1226CrossRefPubMedPubMedCentral Scholmerich J, Schacherer D (2004) Diagnostic biopsy for hepatocellular carcinoma in cirrhosis: useful, necessary, dangerous, or academic sport? Gut 53:1224–1226CrossRefPubMedPubMedCentral
34.
go back to reference Forner A, Vilana R, Ayuso C, et al. (2008) Diagnosis of hepatic nodules 20 mm or smaller in cirrhosis: prospective validation of the noninvasive diagnostic criteria for hepatocellular carcinoma. Hepatology 47:97–104CrossRefPubMed Forner A, Vilana R, Ayuso C, et al. (2008) Diagnosis of hepatic nodules 20 mm or smaller in cirrhosis: prospective validation of the noninvasive diagnostic criteria for hepatocellular carcinoma. Hepatology 47:97–104CrossRefPubMed
35.
go back to reference Durand F, Regimbeau JM, Belghiti J, et al. (2001) Assessment of the benefits and risks of percutaneous biopsy before surgical resection of hepatocellular carcinoma. J Hepatol 35:254–258CrossRefPubMed Durand F, Regimbeau JM, Belghiti J, et al. (2001) Assessment of the benefits and risks of percutaneous biopsy before surgical resection of hepatocellular carcinoma. J Hepatol 35:254–258CrossRefPubMed
36.
go back to reference Takamori R, Wong LL, Dang C, Wong L (2000) Needle-tract implantation from hepatocellular cancer: is needle biopsy of the liver always necessary? Liver Transpl 6:67–72PubMed Takamori R, Wong LL, Dang C, Wong L (2000) Needle-tract implantation from hepatocellular cancer: is needle biopsy of the liver always necessary? Liver Transpl 6:67–72PubMed
37.
go back to reference Silva MA, Hegab B, Hyde C, et al. (2008) Needle track seeding following biopsy of liver lesions in the diagnosis of hepatocellular cancer: a systematic review and meta-analysis. Gut 57:1592–1596CrossRefPubMed Silva MA, Hegab B, Hyde C, et al. (2008) Needle track seeding following biopsy of liver lesions in the diagnosis of hepatocellular cancer: a systematic review and meta-analysis. Gut 57:1592–1596CrossRefPubMed
38.
go back to reference Stigliano R, Marelli L, Yu D, et al. (2007) Seeding following percutaneous diagnostic and therapeutic approaches for hepatocellular carcinoma. What is the risk and the outcome? Seeding risk for percutaneous approach of HCC. Cancer Treat Rev 33:437–447CrossRefPubMed Stigliano R, Marelli L, Yu D, et al. (2007) Seeding following percutaneous diagnostic and therapeutic approaches for hepatocellular carcinoma. What is the risk and the outcome? Seeding risk for percutaneous approach of HCC. Cancer Treat Rev 33:437–447CrossRefPubMed
39.
41.
go back to reference Santillan C, Fowler K, Kono Y, Chernyak V (2017) LI-RADS major features: CT, MRI with extracellular agents, and MRI with hepatobiliary agents. Abdom Radiol. doi:10.1007/s00261-017-1291-4 Santillan C, Fowler K, Kono Y, Chernyak V (2017) LI-RADS major features: CT, MRI with extracellular agents, and MRI with hepatobiliary agents. Abdom Radiol. doi:10.​1007/​s00261-017-1291-4
42.
43.
go back to reference Tang A, Hallouch O, Chernyak V, Kamaya A, Sirlin CB (2017) Epidemiology of hepatocellular carcinoma: target population for surveillance and diagnosis. Abdom Radiol. doi:10.1007/s00261-017-1209-1 Tang A, Hallouch O, Chernyak V, Kamaya A, Sirlin CB (2017) Epidemiology of hepatocellular carcinoma: target population for surveillance and diagnosis. Abdom Radiol. doi:10.​1007/​s00261-017-1209-1
44.
go back to reference Darnell A, Forner A, Rimola J, et al. (2015) Liver imaging reporting and data system with MR imaging: evaluation in nodules 20 mm or smaller detected in cirrhosis at screening US. Radiology 275:698–707CrossRefPubMed Darnell A, Forner A, Rimola J, et al. (2015) Liver imaging reporting and data system with MR imaging: evaluation in nodules 20 mm or smaller detected in cirrhosis at screening US. Radiology 275:698–707CrossRefPubMed
45.
go back to reference Tanabe M, Kanki A, Wolfson T, et al. (2016) Imaging outcomes of liver imaging reporting and data system version 2014 category 2, 3, and 4 observations detected at CT and MR imaging. Radiology 281:129–139CrossRefPubMed Tanabe M, Kanki A, Wolfson T, et al. (2016) Imaging outcomes of liver imaging reporting and data system version 2014 category 2, 3, and 4 observations detected at CT and MR imaging. Radiology 281:129–139CrossRefPubMed
47.
go back to reference Eisenhauer EA, Therasse P, Bogaerts J, et al. (2009) New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1). Eur J Cancer 45:228–247CrossRefPubMed Eisenhauer EA, Therasse P, Bogaerts J, et al. (2009) New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1). Eur J Cancer 45:228–247CrossRefPubMed
48.
go back to reference Lencioni R, Llovet JM (2010) Modified RECIST (mRECIST) assessment for hepatocellular carcinoma. Semin Liver Dis 30:52–60CrossRefPubMed Lencioni R, Llovet JM (2010) Modified RECIST (mRECIST) assessment for hepatocellular carcinoma. Semin Liver Dis 30:52–60CrossRefPubMed
50.
go back to reference Wald C, Russo MW, Heimbach JK, et al. (2013) New OPTN/UNOS policy for liver transplant allocation: standardization of liver imaging, diagnosis, classification, and reporting of hepatocellular carcinoma. Radiology 266:376–382CrossRefPubMed Wald C, Russo MW, Heimbach JK, et al. (2013) New OPTN/UNOS policy for liver transplant allocation: standardization of liver imaging, diagnosis, classification, and reporting of hepatocellular carcinoma. Radiology 266:376–382CrossRefPubMed
51.
go back to reference Hayashi PH, Trotter JF, Forman L, et al. (2004) Impact of pretransplant diagnosis of hepatocellular carcinoma on cadveric liver allocation in the era of MELD. Liver Transpl 10:42–48CrossRefPubMed Hayashi PH, Trotter JF, Forman L, et al. (2004) Impact of pretransplant diagnosis of hepatocellular carcinoma on cadveric liver allocation in the era of MELD. Liver Transpl 10:42–48CrossRefPubMed
52.
go back to reference Park JW, Chen M, Colombo M, et al. (2015) Global patterns of hepatocellular carcinoma management from diagnosis to death: the BRIDGE Study. Liver Int 35:2155–2166CrossRefPubMedPubMedCentral Park JW, Chen M, Colombo M, et al. (2015) Global patterns of hepatocellular carcinoma management from diagnosis to death: the BRIDGE Study. Liver Int 35:2155–2166CrossRefPubMedPubMedCentral
53.
go back to reference Bashir MR, Huang R, Mayes N, et al. (2015) Concordance of hypervascular liver nodule characterization between the organ procurement and transplant network and liver imaging reporting and data system classifications. J Magn Reson Imaging 42:305–314CrossRefPubMed Bashir MR, Huang R, Mayes N, et al. (2015) Concordance of hypervascular liver nodule characterization between the organ procurement and transplant network and liver imaging reporting and data system classifications. J Magn Reson Imaging 42:305–314CrossRefPubMed
54.
go back to reference Davenport MS, Khalatbari S, Liu PS, et al. (2014) Repeatability of diagnostic features and scoring systems for hepatocellular carcinoma by using MR imaging. Radiology 272:132–142CrossRefPubMedPubMedCentral Davenport MS, Khalatbari S, Liu PS, et al. (2014) Repeatability of diagnostic features and scoring systems for hepatocellular carcinoma by using MR imaging. Radiology 272:132–142CrossRefPubMedPubMedCentral
55.
go back to reference Joo I, Lee JM, Lee DH, et al. (2016) Liver imaging reporting and data system v2014 categorization of hepatocellular carcinoma on gadoxetic acid-enhanced MRI: comparison with multiphasic multidetector computed tomography. J Magn Reson Imaging. doi:10.1002/jmri.25406 Joo I, Lee JM, Lee DH, et al. (2016) Liver imaging reporting and data system v2014 categorization of hepatocellular carcinoma on gadoxetic acid-enhanced MRI: comparison with multiphasic multidetector computed tomography. J Magn Reson Imaging. doi:10.​1002/​jmri.​25406
56.
go back to reference Sofue K, Sirlin CB, Allen BC, et al. (2015) How reader perception of capsule affects interpretation of washout in hypervascular liver nodules in patients at risk for hepatocellular carcinoma. J Magn Reson Imaging. doi:10.1002/jmri.25094 Sofue K, Sirlin CB, Allen BC, et al. (2015) How reader perception of capsule affects interpretation of washout in hypervascular liver nodules in patients at risk for hepatocellular carcinoma. J Magn Reson Imaging. doi:10.​1002/​jmri.​25094
Metadata
Title
Hepatocellular carcinoma imaging systems: why they exist, how they have evolved, and how they differ
Authors
An Tang
Irene Cruite
Donald G. Mitchell
Claude B. Sirlin
Publication date
01-01-2018
Publisher
Springer US
Published in
Abdominal Radiology / Issue 1/2018
Print ISSN: 2366-004X
Electronic ISSN: 2366-0058
DOI
https://doi.org/10.1007/s00261-017-1292-3

Other articles of this Issue 1/2018

Abdominal Radiology 1/2018 Go to the issue

Invited article

Cirrhosis and LI-RADS

Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.